The Pain Market Outlook to 2011
News Desk
lower back pain, neuralgia/fibromyalgia, diabetic neuropathic ... If
you would like more details on this research report, fill in ...
The Pain Market Outlook to 2011
Published by: Business Insights
Price: $2875
The patient populations for neuropathic and nociceptive pain are large,
and are driven by separate disease trends that necessitate pain relief;
across the seven major markets in 2005 it was estimated that 37.6m
individuals suffered from neuropathic pain and 170.1m suffered from
nociceptive pain. The major constituents of the neuropathic pain market
are lower back pain, neuralgia/fibromyalgia, diabetic neuropathic pain
and pain associated with multiple sclerosis. The nociceptive pain
market is driven by the prevalence of the major indications of
arthritic pain, particularly osteoarthritis and rheumatoid arthritis,
post-operative pain, cancer-related pain and HIV-related pain. Current
management of pain is mostly pharmacological consisting of the use of
opioids, non-opioids and non-steroidal anti-inflammatory drugs
(NSAIDs), as well as adjuvant therapies such as anti-depressants and
anti-convulsants. Although pain is not a new phenomenon, misdiagnosis
and under-treatment continue to prove deleterious to the pain market.
Increased education for patients, physicians, nurses and pharmacists is
an on-going unmet need that must be addressed. Across the seven major
markets, it is forecast that the prevalence of both the neuropathic and
nociceptive markets will increase modestly. It is forecast that the
prevalence of the neuropathic pain market will increase to 39.1m
individuals, which is complimented by the forecast growth of the
nociceptive market to include 164.8m individuals in 2011.
http://www.pharmaceutical-business-review.com/research.asp?guid=rbhc0160